Goh M, McEnany M, Freeman R, Newton M, Kesselheim AS, Outterson K - eClinicalMedicine
Among high-income countries, the G7 and EU countries fall short of revenue targets needed to sustain research for new antibiotic development, with the UK and Italy as notable exceptions. Revenue guarantee incentives could help bridge gaps in antibiotic investment in wealthier countries amid a growing threat of antimicrobial resistance.
VIEW SOURCE
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
Daval CJR, Kesselheim AS - STAT
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine